Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKM-080301 in Advanced Solid Tumors
NCT01262235Phase 2Completed
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Dec 2010
- Primary completion
- Jul 2015
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of TKM-080301 in solid tumor, lymphoma, Neuroendocrine Neoplasm (NEN), adrenocortical carcinoma (ACC), sponsored by Arbutus Biopharma Corporation. Started Dec 2010; status: completed.
02
Drugs
TKM-080301
03
Conditions
solid tumorlymphomaNeuroendocrine Neoplasm (NEN)adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT01262235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262235.